Literature DB >> 7894536

Effects of lamotrigine on absence seizures in rats.

C M van Rijn1, E W Weyn Banningh, A M Coenen.   

Abstract

Lamotrigine, a novel antiepileptic drug thought to inhibit the excitatory neurotransmitter release and indicated for convulsive seizures, was tested for its efficacy in modulating non-convulsive seizures of the absence type of epilepsy. This was done in a rat model for absence epilepsy: the WAG/Rij strain of rats. In side-effect free doses, lamotrigine did not inhibit absence seizures in these animals. Only in a high dose a reduction of spike-wave activity was noticed, but in that dose side-effects such as abnormal locomotion, were also seen. These findings underline the differential pharmacological profile of convulsive and non-convulsive generalized epilepsy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7894536

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  5 in total

Review 1.  Typical absence seizures and their treatment.

Authors:  C P Panayiotopoulos
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Head-to head comparison of mGlu1 and mGlu5 receptor activation in chronic treatment of absence epilepsy in WAG/Rij rats.

Authors:  V D'Amore; I Santolini; R Celli; L Lionetto; A De Fusco; M Simmaco; C M van Rijn; E Vieira; S R Stauffer; P J Conn; P Bosco; F Nicoletti; G van Luijtelaar; R T Ngomba
Journal:  Neuropharmacology       Date:  2014-05-20       Impact factor: 5.250

Review 3.  Treatment of typical absence seizures and related epileptic syndromes.

Authors:  C P Panayiotopoulos
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.

Authors:  A S Bazyan; G van Luijtelaar
Journal:  ISRN Neurol       Date:  2013-05-07

Review 5.  Establishing Drug Effects on Electrocorticographic Activity in a Genetic Absence Epilepsy Model: Advances and Pitfalls.

Authors:  Gilles van Luijtelaar; Gerard van Oijen
Journal:  Front Pharmacol       Date:  2020-04-14       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.